Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10158480 | Journal of Pharmacological and Toxicological Methods | 2018 | 5 Pages |
Abstract
In this limited analysis performed on the IQ-CSRC study waveforms using FDA's automated algorithm, J-Tpeak prolongation was observed on moxifloxacin, but not on dolasetron, despite clinical observations of proarrhythmias with both drugs. Challenges for the implementation of the J-Tpeak interval as a replacement or complement to the QTc interval, include to demonstrate that the proposed clinical algorithm using a J-Tpeak threshold of 10â¯ms, can be used to categorize drugs with a QT effect up to ~20â¯ms as having low pro-arrhythmic risk.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Borje Darpo, Jean-Philippe Couderc,